NextGen HealthTirzepatide
Ordered Tirzepatide from NextGen Health? Mail in a sample (US only) and let us test it for free.
Test my supplyNextGen Health's Tirzepatide has a low-concern profile under the purity-focus method, with identity passes, 99.68–99.81% purity, and -9% to -1% fill variance. Confidence is tempered by the small run and missing batch IDs on earlier tests.
Florida filings and archive captures tie the storefront to a named operator while undercutting its claimed history. The report also maps COA provenance, a sister fitness brand and referral-code promotion that often reads like organic community chatter.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including NextGen Health rows.
Cancel anytime
About NextGen Health test results from Finnrick
NextGen Health is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 2 peptides and 6 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible NextGen Health peptides in this dataset are Retatrutide (2 tests), Tirzepatide (4 tests) and Melanotan II (0 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 6 recent tests.
Ordered Tirzepatide from NextGen Health? Mail in a sample (US only) and let us test it for free.
Test my supply